Introduction
Conventional targets in diabetes
Recent targets in diabetes
PPAR (Peroxisome proliferator-activated receptors)
GIP (Glucose-dependent insulinotropic polypeptide)
Mechanism
G-Protein coupled receptor (GPCR 119)
FFA 1 (Free fatty receptor-1)
Types | Characteristics | References |
---|---|---|
Short-chain fatty acids (SCFAs) | 1–6 carbon atoms | [46] |
Medium-chain fatty acids (MCFAs) | 7–12 carbon atoms | [46] |
Long-chain fatty acids (LCFAs) | 12 carbon atoms | [46] |
Melatonin
Future targets
Compound | Class | Mode of action | Potential role in diabetes | References |
---|---|---|---|---|
11β Hydroxysteroid dehydrogenase | Glucocorticoids | High levels cause glucose intolerance | By inhibiting 11β-HSD Decrease in blood glucose levels, improved insulin sensitivity | [55] |
ACRP-30 | Hormone | Low levels cause insulin sensitivity | Increase in Acrp30 will increase the insulin sensitivity and decrease in blood glucose levels | |
FETUIN-A | Glycoprotein | Involved in the inflammation of the β-cells | Low levels of Fetuin-A will increase the insulin sensitivity | [59] |
VISFATIN | Protein | Attaches to the insulin receptor | Insulin-mimetic action | [60] |
METRNL | Adipokine | Cause up regulation of the PPARγ pathway | Increase in the insulin sensitivity | [61] |
PEDF (Pigment epithelium-derived factor) | Glycoprotein | Increase kinase-mediated Serine/Threonine phosphorylation cascade of IRS which causes insulin resistance | Decreasing level of PEDF increases the insulin sensitivity | [64] |
VASPIN (SERPIN A12) | Serum glycoprotein | Vaspin performs its action by inhibiting the KLK7 | Due to inhibition of KLK7, insulin signalling is improved and also the half-life of insulin is increased that helps in decreasing the blood glucose levels | |
GPER (G protein-coupled estrogen receptor) | Glycoprotein | Regulation of glucose homeostasis by binding to both Gi/o and Gs proteins | Increase insulin secretion | |
GENE THERAPY | Gene | Act by correcting or repairing the defective genes | Suppression of auto reactive T cells to stop islet cells destruction |
11β Hydroxysteroid dehydrogenase
ACRP-30
ACRP-30 FUNCTIONS | ||
---|---|---|
Actions | Target tissue | References |
Reduces plasma glucose concentration | Entire body system | [81] |
Improves insulin action | Liver | [81] |
Upsurges fatty acid oxidation & reduces plasma fatty acid concentration | Skeletal muscle | [80] |
FETUIN-A
Visfatin
Types of Visfatin in different Human Tissues | |||
---|---|---|---|
Tissue or cell | Type of Visfatin | Method of Determination | References |
Subcutaneous adipose tissue | Visfatin mRNA | RT-PCR | [92] |
Visceral adipose tissue | Visfatin mRNA | RT-PCR | [93] |
Macrophages | Visfatin protein | Immunohistochemistry | [94] |
3T3-L1 cell line | Visfatin mRNA | RT-PCR, Immunohistochemistry | [95] |
Monocytes | Visfatin protein | Immunohistochemistry | [96] |
Lymphocytes | Visfatin mRNA | RT-PCR | [97] |
Skeletal muscle | Visfatin mRNA | RT-PCR | [92] |
Placenta | Visfatin mRNA | RT-PCR | [89] |
Fetal membranes | Visfatin protein | Northern blot | [98] |
GI (colonic epithelium) | Visfatin mRNA | RT-PCR | [94] |
Synovial fluid | Visfatin protein | ELISA | [99] |
Plasma | Visfatin protein | ELISA, RIA | [100] |
Stimulators and inhibitors of Visfatin | ||
---|---|---|
Stimulators | Inhibitors | Reference |
Hypoxia, Hyperglycemia, Inflammation, TNF-alpha, IL-6, IL-1 beta, Chronic Kidney Disease, Labor/Pregnancy, PCOS(polycystic ovary syndrome), Cancer, HAART (highly active antiretroviral therapy), Spironolactone, CoCl2 (hypoxia mimetic agent) Macrostemonoside A | Insulin, Somatostatin, Monounsaturated fatty acid (e.g. oleate) | [89] |
Metrnl
Sample size | Criteria | Results/ conclusion | References |
---|---|---|---|
139 subjects (47 subjects with normal glucose tolerance, 46 subjects with prediabetes, and 46 newly diagnosed T2D patients) | People with type 1 diabetes, gestational diabetes, active hepatitis/liver cirrhosis, chronic renal failure while on hemodialysis, congestive heart failure, or other major diseases were excluded | Lower serum Metrnl levels in subjects with newly diagnosed diabetes compared with those without diabetes | [104] |
170 subjects (66 patients with CAD, 63 T2D patients and 41 controls) | Patients with > 70% stenosis in at least one coronary artery were diagnosed with CAD. Participants with history and evidence of stroke, myocardial infarction, etc. or using thiazolidinedione family drugs were excluded | Lower serum Metrnl in CAD and T2D patients compared to the control group | [105] |
20 subjects (11 healthy controls, 9 patients with newly diagnosed T2D) | No other major diseases and treatment | Lower circulating Metrnl in people with newly diagnosed T2D | [106] |
800 subjects (400 patients with T2D and 400 non-diabetes) | Over 40 years of age without a history of cardiovascular disease, without stage 2 hypertension, malignant disease, severe renal or hepatic disease | Blood Metrnl increased in patients with T2D | [107] |
228 subjects (124 non-diabetes [73 non-obese and 51 obese] and 104 T2D [38 non-obese and 66 obese]) | BMI > 30 kg/m2 were considered obese; Morbidly obese patients (BMI > 40 kg/m2) or subjects taking medication or supplements known to influence body composition or bone mass were excluded | Increased blood Metrnl in T2D and obesity | [108] |
160 subjects (40 subjects with normal glucose tolerance, 40 subjects with impaired fasting glucose, 40 subjects with impaired glucose tolerance, and 40 patients newly diagnosed T2D) | Patients with previously diagnosed T2D, other types of diabetes, other major diseases, and medication history including the use of antidiabetics, statins, diuretics, corticosteroids, estrogen, and progestin were excluded | Increased Blood Metrnl in patients with T2D and significantly increased in patients with prediabetes compared with individuals with normal glucose tolerance | [109] |
260 subjects (89 subjects with normal glucose tolerance, 77 subjects with glucose tolerance impairment and 94 with T2D) | BMI < 35 kg/m2; age between 20 and 75 years; no other CVD; no history of malignancy or recent infection; no history of taking antidiabetic medications, concomitant medications such as systemic steroids, cholestyramine, statins, diuretics, β-blockers, or oral anticoagulants | Decreased serum Metrnl level in patients with T2D versus subjects with normal glucose tolerance | [110] |
89 subjects (59 T2D with durations ≥ 1 year and 30 healthy participants) | Patients with other types of diabetes and other major diseases were excluded | Increased blood Metrnl in patients with T2D. No relationship between Metrnl level and obesity-related indicators | [111] |